Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease

OBJECTIVE: We assessed the effect of canagliflozin, an sodium-glucose co-transporter type-2 inhibitor, on hepatic steatosis using three imaging modalities: magnetic resonance imaging (MRI), computed tomography, and transient elastography. We further determined factors associated with improving hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimiya, Noriko, Tajima, Kazuki, Imajo, Kento, Kameda, Akiko, Yoshida, Eiko, Togashi, Yu, Aoki, Kazutaka, Inoue, Tomio, Nakajima, Atsushi, Utsunomiya, Daisuke, Terauchi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627812/
https://www.ncbi.nlm.nih.gov/pubmed/33994437
http://dx.doi.org/10.2169/internalmedicine.7134-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627812/
https://www.ncbi.nlm.nih.gov/pubmed/33994437
http://dx.doi.org/10.2169/internalmedicine.7134-21

Ejemplares similares